NCT07087184 Gauging Outcomes of Total Milk Ingestion on Lipid and gControl
| NCT ID | NCT07087184 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of California, San Francisco |
| Condition | Heart Diseases |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2025-07-24 |
| Primary Completion | 2027-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 100 participants in total. It began in 2025-07-24 with a primary completion date of 2027-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Atherosclerotic cardiovascular disease remains the leading cause of death for adults in the United States. The cardiovascular impact of milk consumption remains a matter of long-standing scientific debate. Current guidelines for Americans recommend three daily servings of fat-free or low-fat (1%) dairy over full-fat options due to concerns that saturated fat may increase cardiovascular risk. Yet, the literature does not consistently support non-fat dairy as superior to high-fat dairy for reducing cardiometabolic risk. Identifying the comparative health benefits of non-fat versus high-fat dairy milk would be immediately applicable to patients who seek cardiovascular care. In this randomized, case-crossover trial, the investigators seek to efficiently assess the association between high-fat versus non-fat dairy milk consumption and insulin resistance. Utilizing the Eureka Platform, participants will be randomized to limit their liquid milk consumption to whole milk followed by skim milk (or vice versa), measuring the effect of milk fat content on glycemic index and lipid profile.
Eligibility Criteria
Inclusion Criteria: * Are age ≥18 years * Have a smartphone * Are able to use the Eureka mobile application * Consume, on average, at least one cup of dairy milk daily, at least 5 days per week Exclusion Criteria: * Non-English speaker * Are lactose intolerant * History of myocardial infarction * History of type I or type II diabetes * Familial hypercholesterolemia * Plan to change treatment for cholesterol * Unable to read or sign to provide informed consent
Contact & Investigator
Gregory M Marcus, MD, MAS
PRINCIPAL INVESTIGATOR
University of California, San Francisco
Frequently Asked Questions
Who can join the NCT07087184 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Heart Diseases. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07087184 currently recruiting?
Yes, NCT07087184 is actively recruiting participants. Contact the research team at greg.marcus@ucsf.edu for enrollment information.
Where is the NCT07087184 trial being conducted?
This trial is being conducted at San Francisco, United States.
Who is sponsoring the NCT07087184 clinical trial?
NCT07087184 is sponsored by University of California, San Francisco. The principal investigator is Gregory M Marcus, MD, MAS at University of California, San Francisco. The trial plans to enroll 100 participants.